Loading…
Employees: 67
Size Hyundai Bioscience (048410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $401M, the 393rd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩5,640 on 6 Nov 2026.
Performance Over six months the shares fell 57.9%, against -14.5% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 78.0% over the last twelve months (peer median +8.6%); the operating margin is -580.2% (peer median -1.8%).
Valuation It trades at 158.2× enterprise value to sales against a peer median of 5.2× (most expensive of 18).
Capital Return on invested capital runs 24.7 points below its cost of capital (7.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩3.32B | ₩3.52B | ₩15.1B | ₩9.48B | ₩7.85B |
| Revenue growth | — | -77% | +59% | +21% | — |
| Gross profit | -₩1.00B | -₩1.03B | ₩11.2B | ₩3.92B | ₩1.95B |
| EBITDA | -₩17.8B | -₩16.9B | ₩1.47B | -₩8.37B | -₩24.5B |
| Net income | -₩26.5B | -₩22.1B | -₩6.93B | -₩14.5B | -₩15.8B |
| Free cash flow | -₩17.7B | -₩18.6B | ₩1.65B | -₩6.84B | -₩17.6B |
| Capital expenditure | ₩1.01B | ₩20.2B | ₩2.17B | ₩588M | ₩1.54B |
| Total debt | ₩22.8B | ₩17.8B | ₩26.6B | ₩5.55B | ₩6.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 048410.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.6% | -9.4% | 2nd lowest of 21 |
| 6-month return | -57.9% | -14.5% | 2nd lowest of 21 |
| Distance from 52-week high | -73.8% | -34.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +78.0% | +8.6% | 4th highest of 18 |
| Operating margin | -580.2% | -1.8% | lowest of 18 |
| EV / Sales | 158.2× | 5.2× | most expensive of 18 |
| ROIC minus cost of capital | -24.7 pp | -6.4 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 1.5× | 2.8% | +0.3% |